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Background
As the novel pandemic influenza A
(H1N1) (pH1N1) virus spread around the
world in late spring 2009 with a well-
matched pandemic vaccine not immedi-
ately available, the question of partial
protection afforded by seasonal influenza
vaccine arose. Coverage of the seasonal
influenza vaccine had reached 30%–40%
in the general population in 2008–09 in
the US and Canada, following recent
expansion of vaccine recommendations.
Serology studies demonstrated a lack of
cross-reactive antibody to the novel virus
in vaccinated and unvaccinated people
under 60 years of age, suggesting that
there would be no protection against
pandemic influenza from natural immuni-
ty or seasonal vaccination [1]. By contrast,
about one third of seniors over 60 y had
cross-reactive antibodies [1], perhaps due
to childhood exposure to antigenically
similar A/H1N1 viruses. As a result, the
mean age of pandemic cases and deaths
was younger than that of interpandemic
seasons [2], a signature age shift also
experienced in three historical influenza
pandemics [3].
Unexpected Findings in a
Sentinel Surveillance System
The spring 2009 pandemic wave was
the perfect opportunity to address the
association between seasonal trivalent
inactivated influenza vaccine (TIV) and
risk of pandemic illness. In this issue of
PLoS Medicine, Danuta Skowronski and
colleagues report the unexpected results of
a series of Canadian epidemiological
studies suggesting a counterproductive
effect of the vaccine [4]. The findings are
based on Canada’s unique near-real-time
sentinel system for monitoring influenza
vaccine effectiveness. Patients with influ-
enza-like illness who presented to a
network of participating physicians were
tested for influenza virus by RT-PCR, and
information on demographics, clinical
outcomes, and vaccine status was collect-
ed. In this sentinel system, vaccine effec-
tiveness may be measured by comparing
vaccination status among influenza-posi-
tive ‘‘case’’ patients with influenza-nega-
tive ‘‘control’’ patients. This approach has
produced accurate measures of vaccine
effectiveness for TIV in the past, with
estimates of protection in healthy adults
higher when the vaccine is well-matched
with circulating influenza strains and
lower for mismatched seasons [5]. The
sentinel system was expanded to continue
during April to July 2009, as the pH1N1
virus defied influenza seasonality and
rapidly became dominant over seasonal
influenza viruses in Canada.
Additional Analyses and
Proposed Biological
Mechanisms
The Canadian sentinel study showed
that receipt of TIV in the previous season
(autumn 2008) appeared to increase the
risk of pH1N1 illness by 1.03- to 2.74-fold,
even after adjustment for comorbidities,
age, and geography [4]. The investigators
were prudent and conducted multiple
sensitivity analyses to attempt to explain
their perplexing findings. Importantly,
TIV remained protective against seasonal
influenza viruses circulating in April
through May 2009, with an effectiveness
estimated at 56% (41%–67%), suggesting
that the system had not suddenly become
flawed. TIV appeared as a risk factor in
people under 50 y, but not in seniors—
although senior estimates were imprecise
due to lower rates of pandemic illness in
that age group. Interestingly, if vaccine
were truly a risk factor in younger adults,
seniors may have fared better because
their immune response to vaccination is
less rigorous [6].
Because of the potential public health
seriousness of the findings, complementary
observational studies were launched in
Ontario and Quebec, based on hospital
and community cases and controls. These
studies confirmed TIV as a risk factor for
2009 pH1N1 illness, but were somewhat
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Linked Research Article
This Perspective discusses the fol-
lowing study published in PLoS
Medicine:
Skowronski DM, De Serres G, Cro-
croft N, Janjua NZ, Boulianne N, et
al. (2010) Association between the
2008–09 Seasonal Influenza Vaccine
and Pandemic H1N1 Illness during
Spring–Summer 2009: Four Obser-
vational Studies from Canada. PLoS
Med 7(4): e1000258. doi:10.1371/
journal.pmed.1000258
In three case-control studies and a
household transmission cohort, Da-
nuta Skowronski and colleagues
find an association between prior
seasonal flu vaccination and in-
creased risk of 2009 pandemic
H1N1 flu.
PLoS Medicine | www.plosmedicine.org 1 April 2010 | Volume 7 | Issue 4 | e1000259reassuring in that TIV did not increase
severity of disease. Finally, a household
study in Quebec did not show a convinc-
ing difference in secondary attack rates by
vaccination status, although the statistical
power was rather limited.
The authors proposed several biological
mechanisms to explain why seasonal
vaccination may increase the risk of
pandemic illness [4]. One mechanism
involves lack of heterosubtypic immunity
in recipients of TIV, as heterobsutypic
immunity may be generated through T
cell responses during natural infection with
seasonal influenza viruses, but not through
vaccination. This explanation remains
hypothetical, as biological evidence of
heterosubtypic immunity in humans is
scarce despite circumstantial evidence
from past pandemics [7,8]. Other pro-
posed mechanisms were original antigenic
sin and antibody-dependent enhance-
ment, whereby TIV may induce high
antibody titers to seasonal influenza virus-
es, which may cross-react with pH1N1
without neutralizing it, and counteract
development of a robust antibody re-
sponse to pandemic influenza infection.
However, the evidence that antibody
response in human populations depends
on the sequence of past influenza infec-
tions remains debated. Overall, full char-
acterization of baseline pre-pandemic
immune profiles of recipients of inactivat-
ed and live-attenuated seasonal influenza
vaccines and of unvaccinated individuals
of various ages, would be highly informa-
tive to basic science and public health.
Hopefully, such key studies can still be
conducted in part by analysis of stored
blood bank sera.
Potential Biases and Findings
from Other Countries
The Canadian authors quickly found
themselves at odds with expert review
committees who were not convinced by
the data and largely dismissed the findings
as due to confounding bias—a fair criti-
cism of observational studies. To their
credit, the authors had thoroughly assessed
potential biases in their article [4], in
particular relative to the selection of
controls and differences in health care–
seeking behavior, and repeated the study
in different Canadian provinces. They also
provided a full description of their study
population and carefully compared vac-
cine coverage and prevalence of comor-
bidities in controls with national or
province-level age-specific estimates—the
best one can do short of a randomized
study. In parallel, profound bias in obser-
vational studies of vaccine effectiveness
does exist, as was amply documented in
several cohort studies overestimating the
mortality benefits of seasonal influenza
vaccination in seniors [9].
Given the uncertainty associated with
observational studies, we believe it would
be premature to conclude that TIV
increased the risk of 2009 pandemic
illness, especially in light of six other
contemporaneous observational studies in
civilian populations that have produced
highly conflicting results (see Table 1 for
details on study design, population sam-
pled, and results) [10–15]. We note the
large spread of vaccine effectiveness esti-
mates in those studies; indeed, four of the
studies set in the US and Australia did not
show any association [12–15], whereas
two Mexican studies suggested a protective
effect of 35%–73% [10,11]. The most
recent Canadian study in this issue of PLoS
Medicine [4] is clearly at odds with these
results, with an estimated average negative
effectiveness of 268% based on their
Sentinel system. Only one study, set in
the US military population, potentially
corroborated the findings of the Canadian
study [16].
Table 1. Comparison of observational studies evaluating the effectiveness of seasonal influenza vaccination to prevent 2009 pA/
H1N1 morbidity in civilian populations.
Reference Study Setting Study Design
Sample Size (% of
Young Adults) Outcome
Vaccine Effectiveness
Estimate
a (95% CI)
Skowronski et al. [5] Canada; 17 April to 22
July 2009 (first wave)
Sentinel test-negative case
control; community-based GPs
b
144 cases, 536 controls
(49% aged 20–49 y)
2009 H1N1pdm
RT-PCR-confirmed
268% (2174% to
23%)
b, c
Garcia-Garcia et al. [10] Specialty hospital,
Mexico City, Mexico; 29
March to 20 May 2009
Matched hospital case-control 60 cases; 180 controls
(63% aged 21–60 y)
2009 H1N1pdm
RT-PCR-confirmed
73% (34% to 89%)
d
Echevarria-Zuna
et al. [11]
Mexico, 28 April to 31
July 2009
Prospective surveillance (case-
negative controls in inpatients
and outpatients)
1,766 cases; 8,096
controls (N/A)
2009 H1N1pdm
RT-PCR-confirmed
35% (23% to 45%)
Kelly et al., [12] Victoria state, Australia;
27 April to 12 July 2009
Sentinel test-negative case
control; community-based GPs
212 cases; 365 controls
(54% aged 20–49 y)
2009 H1N1pdm
RT-PCR-confirmed
3% (256% to 40%)
e
Gargiullo et al., [13] Eight states, USA;
May–June 2009
Case-based (ie, case- cohort) 356 cases; vacc coverage
sample size=20,689
(77% aged 18–49 y)
2009 H1N1pdm
RT-PCR-confirmed
210% (246% to 15%)
d
Iuliano et al., [14] University of Delaware
outbreak, USA; 27
March to 9 May 2009
Online retrospective survey 7,450 respondents
(90% aged 18–49 y);
677 had ILI
ILI (fever, sore
throat or cough)
210% (240% to 10%)
d
Lessler et al., [15] New York city school
outbreak, USA; April
2009
Online retrospective survey 2,225 respondents
(0% over age 20 y);
694 had ILI
ILI (fever, sore
throat or cough)
25% (220% to 9%)
All studies were conducted during the first wave of the 2009 pandemic (April–July 2009) and most include a majority of young adults.
aNegative estimates of vaccine effectiveness indicate that vaccination may be a risk factor for 2009 pandemic illness, while positive estimates suggest a protective effect.
bThree other study designs are considered in this publication but the Sentinel system is the most well-established.
cAdjusted for age, comorbidities, province, interval between symptoms onset and sample collection.
dAdjusted for age and comorbidities.
eAdjusted for age.
ILI, influenza like illness.
doi:10.1371/journal.pmed.1000259.t001
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prone to bias due to lack of randomiza-
tion. Perhaps the more extreme Canadian,
US, and Mexican studies were deeply
biased, or perhaps the population experi-
ences were truly different due to their
vaccination histories and past influenza
exposure. Given the sudden spread of the
pandemic virus, it would have been
extremely difficult to design a prospective
(randomized) trial to evaluate TIV effec-
tiveness—and such a study is now forever
complicated by pandemic vaccination
efforts.
Policy Implications and a Way
Forward
The putative association between sea-
sonal vaccination and 2009 pH1N1 illness
remains an open question, given the
conflicting evidence from available re-
search. Canadian health authorities de-
bated whether to postpone seasonal vacci-
nation in the autumn of 2009 until after a
second pandemic wave had occurred, but
decided to follow normal vaccine recom-
mendations instead, in part because of
uncertainty about a resurgence of seasonal
influenza viruses during the 2009–10
season [17]. This illustrates the difficulty
of making policy decisions in the midst of a
public health crisis, when officials must
rely on limited and possibly biased evi-
dence from observational data, even in the
best possible scenario of a well-established
sentinel monitoring system already in
place.
What happens next? Given the timeli-
ness of the Canadian sentinel system, data
on the association between seasonal TIV
and risk of pH1N1 illness during the
autumn 2009 pandemic wave will become
available very soon, and will be crucial in
confirming or refuting the earlier Canadi-
an results. In addition, evidence may be
gained from disease patterns during the
autumn 2009 pandemic wave in other
countries and from immunological studies
characterizing the baseline immunological
status of vaccinated and unvaccinated
populations. Overall, this perplexing ex-
perience should teach us how to best react
to disparate and conflicting studies and
prepare us for the next public health crisis,
so that we can better manage future alerts
for unexpected risk factors.
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